

India

Support for Vaccine: Pneumococcal conjugate vaccine (PCV)

This Decision Letter sets out the Programme Terms of a Programme

1.	Country: India
2.	Vaccine grant number: IND-PCV-R
3.	Date of Decision Letter: 12 October 2020
4.	Date of the Partnership Framework Agreement: 16 June 2015
5.	Programme title: New Vaccine Support (NVS), Pneumococcal conjugate vaccine (PCV), Routine
6.	Vaccine type: Pneumococcal conjugate vaccine (PCV)
7.	Requested product presentation and formulation of vaccine: PCV13, 4 doses/vial, liquid
8.	Programme duration: ¹ 2017-2021

9. Programme Budget (indicative):² (subject to the terms of the Partnership Framework Agreement,

if applicable)									
	2017-2020	2021	2022	2023	2024	2025	Total ²		
Programme Budget(US\$)	179,691,526	19,999,489	-	-	-	-	199,691,015		

10. Vaccine introduction grant:

Not applicable

11. Product switch grant:

Not applicable

¹This is the entire duration of the programme.

³This is the amount that Gavi has approved.

²This is the total amount endorsed by Gavi for the entire duration of the programme.

Starting January 2020, a separate Decision Letter for devices only, including historical value of devices will be discontinued. Vaccine programme decision letters issued since January 2020 contain associated devices, however devices in relation to years prior to 2020 are no longer included in decision letters.



12. Indicative annual amounts:³

(subject to the terms of the Partnership Framework Agreement, if applicable)

Type of supplies to be purchased with Gavi funds	2017-2020	2021	2022
Number of vaccine doses	-	6,823,400	-
Number of AD syringes	-	-	-
Number of re-constitution syringes	-	-	-
Number of safety boxes	-	-	-
Annual Amounts (US\$)	179,691,526	19,999,489	-

13. Procurement agency: UNICEF Supply Division

14. Self-procurement:

Not applicable

15. Co-financing obligations:

Not applicable

16. Operational support for campaigns:

Not applicable

Reports	Due dates	
To prep followir		
	 vaccine stock levels including buffer stock, by end of March; 	31 March
	 number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. 	15 May
	 Countries shall report the actual switch date in the first renewal request following the actual implementation. 	
	ordance with applicable Gavi processes, Country shall report on nmatic and financial performance.	To be agree with Gavi Secretariat

18. Financial clarifications:



Not applicable

19. Other conditions:

Not applicable

Signed by, On behalf of Gavi,

F.S.M

Pascal Bijleveld, Director Country Support 15 October 2020